Hormonal
Meeting multiple glycemic criteria (IFG, IGT, and/or elevated HbA1c) for prediabetes significantly increases the risk of progressing to type 2 diabetes compared to meeting only one criterion.
If you have prediabetes, ask your doctor to check all three glycemic markers (fasting glucose, 2-hour post-meal glucose, and HbA1c). Meeting more than one abnormal result means your risk of developing type 2 diabetes is much higher, and you should prioritize intensive lifestyle changes or discuss medication with your provider immediately.
risk for incident T2DM correlates with a number of criteria met, with lowest risk in persons meeting one criterion and highest in those meeting all three prediabetes criteria.
Why this rating
Based on multiple cohort studies (China, Europe, US) showing consistent correlation between criteria count and T2DM incidence.
Source
Reframing prediabetes: A call for better risk stratification and intervention
Sun H. Kim · Journal of Internal Medicine · 2024
DOI 10.1111/joim.13786
More from this paper
- GLP-1 receptor agonists (semaglutide, tirzepatide) induce high rates of reversion to normoglycemia in individuals with prediabetes, but these benefits are largely lost upon discontinuation of the therapy.Strong
- Lifestyle interventions (diet and exercise) reduce the incidence of type 2 diabetes in individuals with prediabetes, but the benefit is primarily established for those with Impaired Glucose Tolerance (IGT) and may not apply to those with isolated Impaired Fasting Glucose (IFG).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →